

Index

- 3'-untranslated regions (UTRs), 139
- 5'-untranslated region (5'UTR), 82
- 1000 genome project, 91, 193, 232, 271, 341, 350
- 1000 Mendelian disease initiative, 350
- aberrant X chromosome, 182
- acute myeloid leukemia (AML), 281
- additive genetic factors, 15
- adiponectin, 75
- adiposity traits, 73
- admixture, 9, 315
- admixture linkage disequilibrium (ALD), 89, 93, 94, 95
- admixture mapping, 100
- adsorption, distribution, metabolism, and elimination (ADME), 300
- adverse drug reaction (ADR), 370, 371
- African ancestry, 72, 99, 330
- African Diaspora SNP chip, 91
- African populations, 13
- African-Americans, 72, 289
- age-related macular degeneration (AMD), 19, 26, 55, 59, 169
- AIDS clinical trials group (ACTG), 306
- alcohol dependence, 171
- alcohol intoxication, 158
- alcohol use disorder (AUD), 151, 153, 156
- allele frequency, 332
- allele-specific methylation, 7, 131, 198
- allelic imbalance (AI), 145
- allelic ratio (AR), 145
- allosteric activation, 290
- alternative polyadenylation (APA), 141
- alternative splicing, 194
- Alu insertion, 321
- Alu repeat frequencies, 259
- Alu-enriched loci, 8
- Alu-enriched regions, 264
- Alzheimer's disease (AD), 250
- amygdala, 163
- ancestral allele, 330
- ancestral north Indian (ANI), 318
- ancestral population, 93
- Andamanese, 315
- aneuploidy, 182
- Angelman syndrome, 124
- ANGPTL4*, 249
- anhedonia, 5
- Annovar program, 271
- anthracycline, 283, 291
- antipsychotic medication, 107
- antiretroviral (ARV) drug toxicity, 303
- antiretroviral (ARV) therapy, 297
- APA-SNPs, 141, 144
- apoptosis, 279
- Appasani, K., 5
- appetite-regulating pathways, 70
- approximate Bayesian polygenic analysis (ABPA), 116
- Arab Gulf Cooperation Council (GCC), 357
- ara-C-resistant variants, 288
- array technology, 178
- array-CGH, 184
- ARV drug resistance, 299, 300
- ARV drugs, 304, 305
- ARV regimen, 301
- Asian populations 304
- assisted reproductive technologies (ART), 128
- association mapping, 43, 44, 48
- asthma, 59
- atazanavir, 303, 304, 305
- atherosclerotic plaques, 84
- ATP-binding cassette subfamily B member 1 gene (*ABCB1*), 302
- attention deficit – hyperactivity disorder (ADHD), 117, 118
- Austroasiatic, 315, 320
- autism, 236
- autism spectrum disorder (ASD), 117, 118
- autoimmune diseases, 59

384 **Index**

- autoimmune disorders, 20
- autoimmune lymphoproliferative syndrome (ALPS), 237
- autosomal dominant, 90
- azathioprine, 370
- Bayes factor testing, 97
- Beadarray, 210
- Beadchip microarrays, 5
- BEAGLE, 209, 333
- behavioral economics, 4, 12
- behavioral variation, 12
- Beijing Genome Institute (BGI), 349
- benzodiazepines, 152
- best linear unbiased prediction (BLUP), 40
- beta-thalasemias, 240
- bilirubin, 303
- Bioconductor package, 210
- biological heterogeneity, 18
- biorepository, 350
- biparental markers, 321
- bipolar disorder, 27, 55, 117, 119
- BMI loci, 74, 75
- BMI-associated loci, 72
- body mass index (BMI), 5, 64, 69
- Botstein, D., 16
- brain reward circuitry, 163
- brain-derived neurotrophic factor (BDNF), 158
- brain-expressed genes, 249
- BRCA1/2* testing, 379
- breakpoint-enriched regions (BERs), 256, 258, 262
- breast cancer, 255, 279
- broad-sense heritability, 28
- built-in replication samples, 53
- cadherins, 330
- calcium channel subunits, 109
- C-alpha test, 92
- cancer, 90, 193, 355
 - evolution, 278
 - hallmarks, 269
 - phenotypes, 271
- cancer cell proliferation, 278
- cancer cell survival, 269
- cancer gene census, 263, 266
- cancer genome, 352
- cancer genome atlas, the (TCGA), 262
 - network, 269, 271
- cancer genomic alterations, 8, 256, 270, 271, 272, 278, 279
- cancer hallmark network framework, 272
- candidate gene studies, 26
- candidate variants, 53
- cardiac rupture, 79
- cardio-metabolic effects, 75
- cardiovascular diseases, 69, 90, 193
- cardiovascular risk profile, 74
- carrier screening, 342
- caste system, 316
- causal/causative genes, 86, 347
- causal variants, 63, 65, 91, 234, 239
- causative SNPs, 144
- CCR5 antagonists, 298
- CD4 Cell membrane, 298
- cell migration, 263
- Center for Cellular and Molecular Biology (CCMB), 318
- Center for Mendelian Genomics, 349
- centimorgans (cM), 93
- Central Drug Research Institute, 318
- central nervous system (CNS) disorders, 59, 151
- centromere instability, 125
- CGH array, 186
- CGS-C allele, 195
- CGS-D allele, 195
- chemokine co-receptor 5 (CCR5), 298
- chemotherapy, 283, 289
- childhood alcohol-dependence symptoms, 157
- Chinese cohort, 82
- chi-square statistics, 333
- chorionicity, 170
- chromatin accessibility, 47
- chromatin modifications (ChIP-seq), 47
- chromatin structure, 187
- chromosomal aneuploidies, 240
- chronic kidney diseases, 99
- cis*-eQTL, 212, 217
- Claritas Genomics, 345, 348
- classical linkage studies, 3
- clinical genomic medicine, 344
- Clinton–Blair agreement, 365
- CNS-associated gene sets, 74
- CNV analysis, 178, 257
- CNV mosaicism, 185
- coding variant, 232
- cognitive domains, 5
- cohort allelic sums test (CAS), 247
- Collins, F., 79, 231
- colorectal cancer, 171
- ComBat, 216
- combined multivariate and collapsing method (CMC), 248
- common disease / common variant (CD/CV), 17, 19
- comparative genomic hybridization (CGH), 175, 255
- complement factor H (CFH), 26
- complex human disease, 53
- complex traits, 14, 17
- comprehensive genetic screens, 358
- congenital anomalies, 169
- congenital diaphragmatic hernia, 169
- congenital heart disease, 169
- consumer testing, 22
- copy number polymorphisms (CNPs), 6, 169

- copy number variation/variants (CNV/CNVs), 6, 119, 169, 236, 257
- coronary artery diseases (CAD), 27, 75, 79
- COSMIC database, 271
- cost–benefit analysis (CBA), 368
- cost-effective analysis (CEA), 368, 369, 375, 376, 377, 378
- costs of goods and services (COGS), 351
- Council of Scientific and Industrial Research (CSIR), 318
- CpG density, 205
- CpG dinucleotides, 125, 194, 197, 198, 200
- CpG Islands, 195, 196, 257
- CpG sites, 130
- CpG-related SNPs (CGSs), 7, 194
- Crohn’s and Colitis Foundation of America (CCFA), 350
- Crohn’s diseases, 18, 27, 54, 59, 60, 245
- cryptic relatedness, 35
- CYP2B6* gene, 300
- CYP2C9**3, 331
- CYP2C19*, 301
- cystic fibrosis, 231
- cytarabine (ara-C), 281, 283, 284, 285
- cytarabine activation, 285
- cytidine deaminase (CDA), 128, 284, 289
- cytidine-5’-triphosphate synthetase (CTPS), 290
- cytochrome P450 isoenzymes, 300
- cytokines, 321
- daunorubicin, 282
- deCODE Genetics, 72
- deoxycytidine kinase (DCK), 284
- deoxycytidylate deaminase (DCTD), 284
- deoxyribonucleoside phosphates, 288
- depression, 155
- developmental origin of health and diseases (DOHaD), 128
- diabetes type 1, 27, 18, 92, 128, 133, 172, 343, 358
- diabetes type 2, 27, 69, 70, 74, 79, 193, 330, 356
- diabetic nephropathy, 75
- Diagnostic and Statistical Manual of Mental Disorders (DSM)*, 106
- diagnostic testing, 239
- dichorionic diamnionic monozygotic (DCDA), 170
- differential methylation, 265
- differential susceptibility, 160
- differentially methylated region 2 (DMR2), 124
- differentially methylated regions (DMRs), 256, 258, 260, 261, 262, 264
- diploid copy number, 175
- DISC1* gene, 107
- disease architecture, 17
- disease gene-mapping, 90
- disease phenotypes, 16
- disease risk, 247
- disease susceptibility, 366
- disease-associated variants, 17, 34
- disease-causing genes, 343
- disease-in-a-dish, 342
- dizygosity, 175
- dizygotic twins, 16, 171
- DNA copy number, 184
- DNA fingerprinting, 361
- DNA methyl transferases (DNMTs), 125
- DNA methylation, 8, 47, 127, 128, 129, 130, 131, 187, 193, 194, 197, 198, 200, 202, 203, 206, 258, 265
 - profiling, 256
- DNA repair, 275
- DNA synthesis, 284, 299
- DNA variations, 169
- dopaminergic systems, 163
- Down syndrome (trisomy 21), 344
- Dravidian, 315
- driving regulator, 272
- DROSHA*, 323
- Drosophila*, 76
- drug resistance, 299
- drug response, 335
- drug screening, 278, 342, 364
- drug therapy, 10, 356
- druggable hits, 21
- DTNBP1* gene, 107
- Duchenne muscular dystrophy, 231
- dyslipidemia, 193, 305
- East Asian ancestry, 62
- East Asians, 64
- economic evaluation, 367, 368, 373
- economic theory, 367
- economics of gene therapy, 372
- EGLN1* gene, 323, 330
- electroencephalography (EEG), 153
- embryogenesis, 123
- embryonic lethality, 126
- ENCODE, 76
- Encyclopedia of DNA Elements (ENCODE) project consortium, 47, 48, 49, 196, 206, 237
- endogamous groups, 316
- endogamy practices, 9, 315
- endophenotypes, 152, 157
- energy metabolism, 74
- English National Health Service (NHS), 370
- enigmatic tribes, 317
- enzyme polymorphisms, 316
- epidemiology, 14
- epigenetic abnormalities, 123
- epigenetic changes, 183
- epigenetic inactivation, 125
- epigenetic marks, 129, 130
- epigenetic mechanisms, 123, 187
- epigenetic modifications, 178
- epigenetic signatures, 187

386 **Index**

- epigenome, 342
 - profiling, 188
- epigenome-wide association studies (EWAS), 5, 123, 131
- epigenomic disease signature, 123
- epigenotype, 131
- epistasis, 28, 114
- epistatic interactions, 22
- epithelial-to-mesenchymal transition, 263
- eQTL
 - analysis, 212, 220, 224
 - electrical diagrams (eQED), 220
 - mapping, 211, 213, 217, 223
- Escherichia coli* two hybrid system, 81
- esophageal atresia, 176, 185
- Estonian biobank, 348, 349
- estrogen receptor alpha 1b gene, 130
- ethnic museum, 315
- ethnicities, 343
- ethnicity-based genome sequencing, 9
- ethnicity-based genomic medicine, 9
- etravirine-resistance-associated mutations (ETV-RAMs), 299
- Eurasians, 64, 322
- European ancestry, 72, 73, 108, 147
- European and African ancestry, 288
- European genetic ancestry, 19
- European genome, 322
- European GWAS, 63, 86
- European populations, 343
- European Union (EU) development, 357
- evolutionary biology, 4, 12
- evolutionary genomics, 323
- evolutionary mixed model for pooled associated testing (EMMPAT), 249
- exome, 352
- exome sequencing, 7, 232, 234, 236, 238
 - prenatal, 240
- expectation-maximization (EM) method, 257
- expression quantitative trait loci (eQTLs)
 - mapping, 7
- expression quantitative traits (eQTs), 6, 21, 46, 208
- family-based linkage studies, 26
- family-based sequencing of affected individuals, 245
- finasteride, 158
- Fisher, R. A., 3, 28
- Fisher's test, 274
- fluorescent *in situ* hybridization (FISH), 175
- Food and Drug Administration (FDA), 298
- fragile X mental retardation syndrome (*FMRI*) gene, 125, 129
- Framingham Heart Study, 69
- FTO* variant, 70
- functional validation, 149
- functional variants, 236
- GABA synapse, 152
- GABA type A receptors, 152, 155
- GABRA2*, 159, 160, 161, 163
- galectin-2, 83
- gastrointestinal atresia, 173
- Gaussian distribution, 39
- Gaussian graphical models (GGM), 220
- gene burden testing, 92
- gene ontology (GO), 219, 274
- gene redundancy, 235
- gene silencing, 139
- gene-centric chip, 73
- gene-environment interactions, 10, 75, 151, 159, 160, 188, 243
- gene-gene interactions, 75, 84
- gene-protein networks, 10
- genetic and environmental factors, 14
- genetic and physical mapping, 7, 231
- genetic architecture, 14, 16, 49, 108, 114, 208
- genetic association studies, 200
- genetic bases of diseases, 334
- genetic disorders, 344
- genetic diversity, 13
- genetic drift, 9, 13, 315
- genetic epidemiology, 14
- genetic etiology 108
- genetic footprints, 317
- genetic heterogeneity, 322
- genetic linkage, 89
- genetic pleiotropy, 75
- genetic polymorphisms, 300, 302, 303
- genetic predisposition, 130
- genetic regulatory network, 220
- genetic risk prediction, 3
- genetic screening, 239
- genetic variations, 208, 238, 290, 306
- genetics of complex disorders, 232
- genome England project, 346, 354
- genome Qatar, 346, 359
- genome rearrangements, 8, 255, 256
- genome sequencing, 92, 342
- genome technology, 8
- genome test, 351
- genome-wide ancestry, 97
- genome-wide complex trait analysis (GCTA), 115
- genome-wide scale, 8
- genome-wide screening, 8
- genome-wide significance, 27
- genome-wide SNP arrays, 175
- genomic diagnostics, 361, 362
- genomic imprinted loci, 131
- genomic instability, 266
- genomic investigation of anthropometric traits (GIANT Consortium), 71
- genomic medicine, 9, 341, 347, 350, 353, 356, 357, 358, 361
- genomic variability, 53

Index

387

- genotype, 196, 335
- genotype matrix, 31, 33
- genotype–phenotype associations, 3, 8, 297, 306
- genotyping, 18, 54, 185, 198, 250, 251
 - array, 73
 - assay, 299
 - chips, 5
- germline transmission, 129
- global enterprise solutions, 359, 360
- glomerular disease, 98
- glucocorticoid receptor (Gr) gene, 127
- GO enrichment analysis, 223
- GU content, 144, 145
- GWAS catalogue, 58
- GWAS meta-analyses, 74
- GWAS paradigm, 26
- GWAS replicability, 54
- HAART-induced lipodystrophy, 305
- hallucinations, 5, 106
- Hamburg and Collins, 9
- Handigodu diseases, 322
- haplogroups, 317, 320
- haploinsufficiency, 168
- HaploReg, 47
- haplotype, 18, 83, 90, 155, 194, 196, 200, 202, 363
- haplotype-tagging, 90, 91
- HapMap Consortium, 90
- HapMap project, 3, 10, 18, 61, 83, 116, 147, 193, 205
- Hapmapr27, 142
- Hardy–Weinberg Equilibrium (HWE), 209
- healthcare, 358, 375
- heart disease, 343, 356
- hematopoietic stem cells, 182
- hemochromatosis gene (*HFE*), 306
- hepatocellular cancers, 62
- heritability, 4, 15, 16, 22, 28, 38, 69, 115
- heritability estimation, 27, 34, 43, 48
- heritable germline epimutation, 129, 131
- heterozygotes, 70, 232
- high-altitude pulmonary edema, 330
- high-density lipoprotein cholesterol (HDL-C), 246, 305
- high-density marker, 318
- high-dimensional prediction, 38
- high-fat diet, 70
- highly antiretroviral therapy (HAART), 298
- Hindu society, 316
- hippocampus, 127, 152
- Hirschhorn and Altshuler, 18
- Hispanic Americans, 70, 72
- Hispanic genetic ancestry, 62
- histocompatibility complex, major (MHC), 109
- histone genes, 263
- histone H3 methylation, 130
- histone modifications, 187
- HIV, 90
- HIV drugs, 301
- HIV infection, 298
- HIV-associated neuropathy, 98
- HL-60 leukemic cell line, 288
- HLA-DRA, 323
- homopolymers, 238
- homozygosity mapping, 7, 231, 236, 237
- homozygous, 70, 232
- human circuitry era, 10
- human coronary artery endothelial cells (HCAEC), 85
- human coronary artery smooth muscle cells (HCAEC), 84
- human disease biology, 5, 252
- human equilibrative nucleoside transporter (hENT1), 285
- human genetic variation, 13, 157
- human genome circa, 350
- human genome era, 10
- human genome project, 17, 26, 193, 349
- human genomic diversity, 53
- Human Longevity, Inc., 347
- human migration, 100
- human population diversity, 62
- human variation, 234
- Huntington’s disease, 178, 231
- hyperbilirubinemia, 303, 304, 305
- hypercholesterolemia, 79
- hyperglycemia, 71, 305
- hyperinsulinemia, 71
- hypermethylation, 127, 202, 204, 260
- hyperphagia, 71
- hypertension, 27, 79
- hypertriglyceridemia, 245, 305
- hypomethylation, 260, 263, 265
- hypopigmentation, 126
- identical-by-descent (IBD) segments, 93, 95
- Illumina DNA sequencing platform, 196
- Illumina HiSeq platform, 345
- immunohistochemistry, 84
- IMPUTE2, 209, 333
- Indian genome variation (IGV) consortium, 318, 323
- Indian Institute of Chemical Biology, 318
- Indian populations, 315, 318
- indinavir therapy, 303
- Indo-European, 315, 331
- induction therapy, 282
- Industrial Toxicological Research Center, 318
- inflammation, 79
- inflammatory bowel disease, 239
- inflammatory diseases, 370
- inheritance pattern, 15
- inherited genetic diseases, 342
- insertion/deletions (inDel), 178
- INSIG2* gene, 69
- insulin resistance, 305
- insulin secretion, 74

388 **Index**

- Institute of Microbial Technology, 318
- integrated networks, 273
- internal tandem duplication (ITD), 282
- international Cancer Genome Consortium, 323
- International Hap Map project, 61, 91
- International HapMap 3 Consortium, 14, 233
- International Schizophrenia Consortium (ISC), 60, 108
- inter-sample correlation (ICE), 216
- interval mapping, 213
- invasion, 263
- IRX3* gene, 71
- JAK/STAT* signaling, 282
- Japanese population, 83
- Kabuki syndrome, 236
- karyotype, 182, 183, 184
- karyotyping, 178
- Lander, E., 17, 21, 26, 79
- large-buoyant low-density lipoprotein cholesterol (IbLDL-C), 305
- large-effect size, 56
- lifetime alcohol problem score, 157
- linear mixed models (LMM), 28, 115
- linear mixed models approach, 32, 33, 41
- linear regression, 36, 197
- linkage analysis, 153, 235
- linkage complex associations, 6
- linkage disequilibrium (LD), 13, 28, 61, 80, 94, 98, 139, 153, 168, 212, 320
- lipoatrophy, 304
- lipodystrophy, 304, 305
- lipohypertrophy, 304
- livestock selection, 12
- logistic regression, 36
- long interspersed elements (LINE), 263
- long-term environmental stimuli, 127
- low-density lipoprotein cholesterol (LDL-C), 305
- low-effect risk variants, 56
- low-effect size, 56
- lymphoblast cell line, 289
- lymphoblastic leukemia, 148
- machine learning technique, 143
- macrophages, 84
- Madras motor neuron diseases, 322
- maladaptive behavior, 162
- MALDI/TOP Mass spectrometry, 83, 352
- MAP kinase family, 271
- MAPK pathways, 271, 274
- marker genotypes, 208
- Markov cluster (MCL) algorithm, 274
- maternally methylated imprinted loci, 128
- mature-onset obesity, 72
- MC4 R* gene, 74
- McCellan and King, 9
- McKusick, V., 7, 109
- medical genetics, 4
- meiosis, 182, 183
- melanocortin-4 receptor (MC4 R), 71
- Mendelian diseases, 5, 7, 90, 92, 231, 237, 356, 358, 363
- recessive, 235, 236
- Mendelian inheritance, 3
- recessive, 236
- Mendelian trait, 6
- mental disorders, 128, 133
- mental illness, 343
- mental stress, 129
- MetaboChip, 73
- metabolic disorders, 128
- metabolic syndrome traits, 27
- metabolome, 342
- methylated cytosine, 200
- methylation chip, 198
- methylation oligonucleotide microarray analysis (MOMA), 256, 257
- methyl-CpG-binding domain proteins (MBDs), 125
- methylome, 257
- methyl-RRBS, 196
- Michigan Longitudinal Study (MLS), 161
- microarray, 175, 208
- microbiome, 342
- microRNA (miRNAs), 6, 139, 246
- million veteran program (MVP), 345, 352, 354, 361
- minimum allele frequency (MAF), 147
- minimum free energy (MFE), 145
- minor allele frequencies (MAF), 21
- miR-125b*, 140
- miR-525-3p*, 148
- mir-571*, 147
- miRNA binding sites, 141
- miRNA regulation, 146
- miRNA target prediction, 143
- miRNA target sites (miRSNPs), 6, 139, 141, 143, 144, 145, 147
- mismatched model structure, 44
- mitochondrial DNA damage, 306
- mitochondrial DNA markers, 316, 317
- mitogen-activated protein (MAP) kinase, 85
- monoallelic expression, 124
- monochromatic diamniotic monozygotic (MCDA), 182
- monogenic obesity, 72
- monozygotic (MZ) twins, 16, 107, 128, 187
- sisters, 184
- monozygous twins, 170, 171, 173, 174, 175, 178
- mosaicism, 182
- motivational enhancement therapy (MET), 155

- mouse insulin-like growth factor 2 (IGF2)
 - gene, 124
- mRNA stability, 141
- multi-drug resistance protein 1 (*MDR1*), 302
- multifactorial diseases, 243
- multiple genomic loci, 123
- multiple system atrophy (MSA), 186
- multiple testing, 18
- myocardial infarction (MI), 5, 62, 79
- myostatin gene, 140
- narrow-sense heritability, 15, 29
- National Center for Advancing Translational Science (NCATS), 349
- national healthcare systems, 365
- National Human Genome Research Institute (NHGRI), 44, 349
- natural selection, 9, 315
- network analysis, 270, 278
- network wiring, 270
- neurodegenerative diseases, 148
- neurodevelopmental delay 126
- neurodevelopmental disorder, 124, 133
- neuronal and axonal mitochondrial injury, 305
- neuropathy, 305
- newborn screening, 362
- next-generation sequencing (NGS), 5, 7, 92, 119, 187, 231, 239, 379
- NGS technologies, 244, 245, 252
- NIH Roadmap Epigenomics project, 76
- Nihalis, 315
- non-allelic homologous recombination (NAHR), 263
- non-coding regions, 47, 139, 237
- non-coding SNPs, 76
- non-Mendelian transmission, 238
- non-nucleoside reverse transcriptase inhibitors (NNRTIs), 298, 299, 300
- Norwegian breast cancer cohort, 256
- nuclear factor κ B (*NfκB*), 81
- nuclear receptor cistrome, 76
- nucleoside reverse transcriptase inhibitors (NRTIs), 298, 305
- nutritional factors, 183
- obesity, 76, 79, 128
- odds ratio (OR), 14
- OncoMine, 344
- online Mendelian inheritance in man (OMIM), 109
- open reading frame (ORF), 223
- organic anion transporting polypeptide, 302
- ovarian cancer, 263
- Ozaki and Tanaka, 5
- PAGE Consortium, 64
- Parkinson's disease, 148, 186
- Parkinson-like discordant monozygotic twins, 186
- paternal imprints, 124
- pathway information, 46
- pathway-based analyses, 75
- Pearson regression, 197
- pediatric leukemia, 283
- pericentromeric, 263
- peripheral neuropathy, 306
- peroxisome proliferator-activated receptor alpha (*PPARα*) gene, 128
- personal biology, 342
- Personalis, 345
- personalized genetic testing, 22
- personalized medicine, 8, 9, 10, 341, 345, 362, 366, 370, 372, 375, 379, 380
- personalized therapy, 291, 334
- phage display, 81
- pharmaADME database, 331
- pharmaco-genetic markers, 8
- pharmaco-genetic traits, 3
- pharmaco-genomic technologies, 367
- pharmacogenomics, 281, 283, 284, 285, 289, 291, 297, 302, 303, 323, 344, 356
 - variants, 330
- pharmacokinetics (PK), 281, 283, 290, 302, 331
- PharmGKB database, 331
- phenotypic coherence, 119
- phenotypic variation, 15
- phenotypical discordant twins, 184
- phylogenetic conservation, 249
- placental anastomoses, 173
- pleiotropy, 44, 116
- PLINK, 36
- poly (A) tail, 141
- polyadenylation signals, 144, 145
- polycystic ovary syndrome, 54
- polygenicity, 27
- polymerase chain reaction (PCR)-invader assay, 79, 80
- polymorphic genetic markers, 4
- polymorphic loss of function (LoF), 234
- polyphagia, 74
- pooled sequencing data, 246
- population genetics, 8
- population genomics, 19
- population screening programs, 363
- population stratification, 18
- population-scale genome sequencing, 353
- post-GWAS analyses, 90
- post-GWAS era, 49
- postnatal disease screening, 240
- post-zygotic mutations, 182
- potassium channels, 330
- Prader–Willi syndrome, 124
- precocious coronary artery diseases (PROCARDIS), 80
- premature death, 69
- primordial germ cells (PGCs), 124
- principal component analysis (PCA), 35, 48, 209, 319

390 **Index**

- programmable DNA nucleases, 76
- proinflammatory factors, 85
- proteasome, 81
- protein kinases, 330
- protein-coding regions, 46
- proteome, 342
- pseudocholinesterase deficiency, 322
- psychiatric diseases, 118
- psychiatric disorders, 44
- Psychiatric Genomics Consortium (PGC), 27
- psychopathology, 160
- p*-values, 26, 55, 57, 117, 219, 223, 249, 274, 332
- quality adjusted life years (QALYs), 370, 378
- quantitative polymerase chain reaction (qPCR), 175, 352
- quantitative traits, 7, 35
- rare genetic disease, 349
- rare mutations, 247
- rare variant association, 247
- recessive association model, 80
- recessive or X-linked, 90
- RegulomeDB, 47
- relative risk (RR), 14
- REML estimator, 41
- reporter gene analysis, 85
- representational oligonucleotide microarray analysis (ROMA), 256
- restriction fragment length polymorphism (RFLP), 16
- retinoblastoma, 231
- retro-transposable SINE elements, 265
- Rett syndrome, 128, 187
- rheumatoid arthritis (RA), 27, 59
- ribonucleotide reductase, 284, 290
- ridge regression, 38, 41, 48
- Risch and Merikangas, 3, 17, 26
- risk genotype, 160
- risk prediction, 48
- RNA polymerase 46
- RNAi knockdown, 269, 270
- RNAi screening, 270, 271, 272
- RNA-induced silencing complex (RISC), 139
- RNA-seq, 47, 208, 225
- ROLLOFF method, 322
- Saudi Arabia, 358
- Saudi genome project, 346, 361
- Saudi population, 345
- Schinzel–Giedion syndrome, 236
- schizophrenia, 5, 106, 117, 119, 171, 178, 236, 250
- schizophrenia-associated genetic variants, 44
- Scripture, 210
- sequence kernel association test, 92
- sequencing technology, 344
- sex determination, 240
- short interspersed elements (SINE), 263
- short-tandem repeats (STRs), 317
- signaling networks, 272, 277
- signaling pathways, 279
- signalosome protein, 85
- SINE Alu elemnts, 266
- single rare variants, 250
- single-gene disorders, 344
- siRNA, 82, 85
- small-density lipoprotein cholesterol (sdLDL-C), 305
- small-effect variants, 48
- SMARTPCA tool, 333
- SNP alleles, 143
- SNP array, 185, 186
 - analysis, 187
- SNP array-based GWAS, 187
- SNP chips, 5
- SNP expression, 146
- SNP genotyping, 90
- SNP microarray, 183
- SNP prioritization, 46
- somatic nuclear transfer, 125
- Soto’s syndrome, 169
- South-Asian ancestry, 72
- spinocerebellar ataxia, 178
- spondylitis, 16
- sporadic diseases, 236
- squamous cell carcinoma, 132
- stakeholders, 362
- statistical genetics, 343
- structural variation (SV), 13
- support vector machines (SVM), 143
- surrogate variable analysis (SVA), 216
- susceptibility locus, 64, 80
- susceptibility variants, 4
- SWITCH-MHMM, 95
- synaptic strength, 151
- tag SNPs, 61, 81, 155, 168, 323
- Taiwan biobank project, 347
- Taiwanese population, 83
- target allele, 145
- telomere extension, 275
- Thangaraj, 9, 315
- Thermo Fisher Enterprise Genomics Solutions Group, 361
- Thermo Fisher ion torrent sequencing proton platform, 345, 351, 354
- Tibeto-Burman, 315
- TopHat, 210
- transcription factor (TF), 46
 - binding site, 47, 215
- transcription factor FOXA 1, 47
- transcription start site (TSS), 195
- transcriptome, 7, 342
- trans*-eQTL, 212, 217
- TRANSFAC database, 85
- translational research, 353

Index	391
transmission disequilibrium test (TDT), 97	visceral fat-associated SNP, 149
transposable elements, 264	Visscher, P., 16, 19, 20, 27, 114
treatment regimens, 282	
tree-structured penalty, 215	Wellcome Trust Case Control Consortium (WTCCC), 4, 19, 27, 55, 56, 57
trial-based evaluation, 372	weak-effect variants, 49
triple-negative breast cancer, 270	whole exome sequencing, 239
Trypanosomes, 98	whole-association mapping, 53
tumor necrosis factor-alpha gene (<i>TNF-alpha</i>), 304	whole-genome sequencing (WGS), 10, 232, 318, 345, 352, 363, 375
tumorigenesis, 266	whole-genome SNPs, 38
twelve-step facilitation (TSF), 155	willingness-to-pay (WTP) techniques, 368
twin pregnancies, 170	WINPOP, 95
twin-to-twin transfusion syndrome (TTTS), 173	World Health Organization (WHO), 282
ubiquitinligase, 85	X chromosome, 125
ulcerative colitis, 323	X-inactivation, 187
under control – disinhibition behavior, 156	
uridine diphosphate-glucuronosyltransferase 1A1 (<i>UGT1A1</i>), 303, 304	Y chromosome, 125, 321
USDA, 206	<i>Yersinia pestis</i> , 321
	Yoruba individuals, 84
vantage-sensitive hypothesis, 162	zinc finger transcription factor, 285
Venter, C., 26	zygosity, 174
ventral tegmental area (VTA), 152	testing, 175
ventricular fibrillation, 79	typing, 175